drugset / Press release
Fresenius Kabi receives positive CHMP opinion for MSB11022, a biosimilar candidate of adalimumab
2019-02-01 · Fresenius Kabi · original fresenius.com ↗
Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira ® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019. *Humira ® is a registered trademark of AbbVie Biotechnology Ltd.
The release as fetched from its publisher. fresenius.com ↗